MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2006 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
122 M |
Market Cap[1] |
$ 3.85 B |
EBITDA (LTM) |
$ 258 M |
P/E (LTM) |
- |
P/S (LTM) |
6.53822 |
EPS (LTM) |
1.75 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
ММЦБ
GEMA
|
- | - | - | MOEX | Russia |
 |
Lyra Therapeutics
LYRA
|
- | - | $ 24.9 M | Nasdaq Global Market | USA |
 |
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | Russia |
 |
Фармсинтез
LIFE
|
- | - | - | MOEX | Russia |
 |
ОЗОН Фармацевтика
OZPH
|
- | - | - | MOEX | Russia |
 |
Промомед
PRMD
|
- | - | - | MOEX | Russia |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
ESSA Pharma
EPIX
|
- | - | $ 8.86 M | Nasdaq Capital Market |  Canada |
 |
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | USA |
 |
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | USA |
 |
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market |  Niderland |
 |
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | USA |
 |
Exicure
XCUR
|
$ 1.05 | -7.08 % | $ 6.61 M | Nasdaq Capital Market | USA |
 |
Cellectis S.A.
CLLS
|
$ 0.98 | 0.51 % | $ 98.3 M | Nasdaq Global Market |  France |
 |
AbCellera Biologics
ABCL
|
$ 11.82 | 3.96 % | $ 3.53 B | Nasdaq Global Select Market | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 58.02 | -0.58 % | $ 7.76 B | Nasdaq Global Select Market,SPB | USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 55.95 | -1.2 % | $ 10.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Celldex Therapeutics
CLDX
|
$ 29.25 | 0.97 % | $ 1.94 B | Nasdaq Global Select Market | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.67 | 1.38 % | $ 44.8 M | Nasdaq Capital Market |  Israel |
 |
Jaguar Health
JAGX
|
$ 2.04 | -5.12 % | $ 4.76 M | Nasdaq Capital Market | USA |
 |
Protalix BioTherapeutics
PLX
|
$ 2.55 | -0.58 % | $ 200 M | NYSE American | Israel |
 |
uniQure N.V.
QURE
|
$ 22.43 | -2.94 % | $ 1.29 B | Nasdaq Global Select Market | Niderland |
 |
Stoke Therapeutics
STOK
|
$ 25.04 | -2.57 % | $ 1.48 B | Nasdaq Global Select Market,SPB | USA |
 |
Xencor
XNCR
|
$ 25.18 | -2.55 % | $ 1.87 B | Nasdaq Global Select Market,SPB | USA |
 |
Annexon
ANNX
|
$ 3.75 | -1.57 % | $ 582 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.78 | -2.73 % | $ 2.93 M | NYSE American | Israel |
 |
Incyte Corporation
INCY
|
$ 115.71 | -1.04 % | $ 22.6 B | Nasdaq Global Select Market,SPB | USA |
 |
Mesoblast Limited
MESO
|
$ 12.28 | -2.15 % | $ 14.8 B | Nasdaq Global Select Market |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
$ 9.21 | -5.73 % | $ 741 M | Nasdaq Global Select Market | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 523.93 | -2.1 % | $ 134 B | Nasdaq Global Select Market,SPB | USA |
 |
Abeona Therapeutics
ABEO
|
$ 4.4 | -1.57 % | $ 233 M | Nasdaq Capital Market | USA |
 |
AbbVie
ABBV
|
$ 285.64 | 0.24 % | $ 505 B | NYSE,SPB | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.16 | -4.11 % | $ 259 K | NYSE American | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.57 | 0.84 % | $ 147 M | Nasdaq Global Market | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.2 | -0.24 % | $ 805 M | Nasdaq Global Select Market | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 19.73 | -2.86 % | $ 3.32 B | Nasdaq Global Select Market,SPB | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.44 | -9.72 % | $ 183 M | NYSE |  Schweiz |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 25.51 | 4.51 % | $ 3.87 B | Nasdaq Global Select Market,SPB | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
$ 0.4 | -5.51 % | $ 29.3 K | Nasdaq Global Market | USA |
 |
Seagen
SGEN
|
- | - | $ 42.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 37.0 | -0.51 % | $ 2.14 B | Nasdaq Global Select Market,SPB | USA |
 |
Oncternal Therapeutics
ONCT
|
- | -24.12 % | $ 1.56 M | Nasdaq Capital Market | USA |
 |
Iterum Therapeutics
ITRM
|
- | - | $ 591 K | Nasdaq Global Select Market |  Irlanda |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Achieve Life Sciences
ACHV
|
$ 6.49 | -0.15 % | $ 283 M | Nasdaq Capital Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Geron Corporation
GERN
|
$ 1.12 | -0.88 % | $ 747 M | Nasdaq Global Select Market | USA |
 |
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.